Shopping


Posts filtered by tags: Boston blog main[x]


 

Bio Roundup: Nationwide’s Rise, a Surgeon’s Quest, CRISPR USA & More

Persistence and perseverance were the themes of two of our top stories this week.First there’s the story of Nationwide Children’s Hospital. The Columbus, Ohio, hospital chose to invest in gene therapy when the field was in its darkest days. After some ups and downs, the team it put in place helped advance some of the most promising gene therapies currently in human testing—and put Nationwide in the national spotlight as one of those treatments nears FDA approval.Then there’s Suzanne Ildstad. A ...
Tags: Deals, Startups, Usa, Trends, Vc, Fda, National, University of Pennsylvania, Novartis, Allergan, Biotech, Crispr, Life Sciences, Clinical Trials, Amgen, Gilead Sciences


$100M For Talaris Gives Surgeon a Shot to Reinvent Organ Transplants

When Novartis dissolved its gene and cell therapy unit a few years ago, a bunch of projects the Swiss pharma giant had incubated were tossed aside. One of them was the work of surgeon Suzanne Ildstad, who has spent decades trying to develop a new way to improve the health outcomes of patients who need organ transplants.That work has just been salvaged. If it plays out as Ildstad hopes, her company might not only help transform treatment for kidney failure patients—but possibly, for people suffe...
Tags: Deals, Startups, Boston, Trends, Vc, National Institutes of Health, Novartis, Stem Cell, Stanford University, Life Sciences, Blackstone Group, Louisville Ky, National blog main, New York blog main, New York top stories, Seattle blog main


Seattle’s Outreach Joins Unicorn Ranks With $114M Funding Round

Another tech “unicorn”—privately controlled startups valued at $1 billion or more—has been minted following sales software company Outreach’s latest venture funding round, a $114 million deal.Seattle-based Outreach develops customer relationship management tools designed to improve communication between salespeople and their prospective clients. Launched in 2013, the startup says its most recent round of financing values Outreach at $1.1 billion and brings its total funding haul to $239 million...
Tags: Deals, Startups, Uber, Pinterest, Microsoft, Sales, Trends, Tech, IPOs, Outreach, Vc, Seattle, Unicorns, Drift, Dfj Growth, Meritech Capital partners


Lyft, Uber, and the Changing Disclosure Rules For Unicorn IPOs

When a much-watched tech company such as Lyft, Uber, or Pinterest files for an initial public stock offering, people eagerly scour the sudden trove of information that such a private business must finally disclose when it begins to offer shares to the general public, rather than only to sophisticated inside investors such as venture capital firms.For newly public company Lyft, (NASDAQ: LYFT) though, the IPO disclosure requirements were significantly lower than they would usually be for business...
Tags: Deals, Startups, Transportation, Mobile, Lyft, Uber, Hardware, Pinterest, Internet, Entrepreneurship, Ipo, Funding, San Francisco, Trends, Tech, Financial Crisis


Thwarting Opposition, Bristol Gets Shareholder OK for $74B Celgene Buyout

The early opposition has turned out to be just noise. Shareholders of Bristol-Myers Squibb today approved the pharma giant’s planned buyout of Celgene, paving the way for a deal that will create one of the largest biopharma organizations in the world, and send ripples throughout the sector. (NYSE: BMY) said Friday that more than 75 percent of its shareholders voted to approve the deal at a meeting on Friday. Some 98 percent (NASDAQ: CELG) of Celgene’s stockholders supported the deal, the compa...
Tags: Deals, New York, Trends, Merck, M&a, Life Sciences, Nyse, Celgene, Bristol-myers Squibb, National blog main, New York blog main, New York top stories, Seattle blog main, Seattle top stories, Boston blog main, National top stories


Boston Tech Watch: Tufin, Facebook, RightHand, Diameter & Jebbit

A cybersecurity IPO could raise up to $124 million for an Israeli-based company with its US headquarters in Boston. Facebook’s Boston office wants to map the world’s population in high def, starting with Africa. More venture cash is flowing into Bay State startups. Read all this and much more in this week’s roundup of local tech news.—Tufin Software Technologies, a cybersecurity company based in Israel with its US headquarters in Boston, went public this week and is listed on the New York Stock...
Tags: Deals, Startups, Facebook, Boston, Softbank, Israel, US, Trends, Tech, Connecticut, Weather Forecast, New York Stock Exchange, Eric Schmidt, Video Game, Affectiva, Healthtech


AskBio Reels In $235M to Advance Gene Therapy Clinical Trials

Asklepios BioPharmaceutical (AskBio) has raised $235 million in financing to support its research and development of gene therapies for rare, genetic disorders.The funding came from TPG Capital and Vida Ventures, which together invested $225 million and gained a minority stake in the Research Triangle Park, NC, company. Concurrent with that investment, AskBio’s founders and board members invested $10 million. The AskBio funding is the latest in a flurry of gene therapy investments that have swe...
Tags: Deals, Drugs, Trends, Investing, Venture Capital, Fda, Pfizer, Parkinson's Disease, Biotech, Tpg Capital, Life Sciences, Clinical Trials, Roche, Thermo Fisher Scientific, Biogen, University of North Carolina at Chapel Hill


Sobriety Pays: DynamiCare Gamifies Staying Clean for Recovering Addicts

Eric Gastfriend was looking for his next tech startup idea after leaving his video game startup Happy Cloud and finishing an MBA at Harvard Business School when the inspiration came from a source close to home.A relative was entering rehab for alcohol abuse for the second time, he says. Gastfriend asked his father—David Gastfriend, director of addiction research at Massachusetts General Hospital—why treatments sometimes don’t seem to stick and people with substance disorders relapse.“My dad sai...
Tags: Deals, Boston, Alcohol, Trends, Tech, App, Substance Abuse, Addiction, Health Tech, VCs, Massachusetts General Hospital, Akili Interactive, Harvard Business School, National blog main, Boston blog main, National top stories


VC Trends in 2019: More Money, Fewer Deals But Women Still Get Less

If you’ve been following venture capital trends, what you expected to happen in the first quarter of 2019 did: More money is being invested in fewer deals, and women founders still are getting less of it than men.Venture firms sent $32.6 billion into startups nationally during the first three months of 2019, the second largest amount for any quarter since at least 2006, according to data released overnight by PitchBook and the National Venture Capital Association. But that large sum came from o...
Tags: Deals, Startups, Lyft, Uber, Hardware, Entrepreneurship, Softbank, Funding, Women, Trends, Tech, Vc, Software, Physics, Pwc, Venture Capital


Alnylam Gets $800M From Regeneron to Bring RNAi to Eye, Brain Diseases

Alnylam and Regeneron Pharmaceuticals are announcing a wide-ranging alliance this morning to co-develop treatments for eye and neurological diseases using RNA interference, a method of drugmaking that has recently come of age after years of ups and downs.Regeneron (NASDAQ: REGN), of Tarrytown, NY, will pay Alnylam (NASDAQ: ALNY) $400 million in cash up front and buy $400 million in Alnylam stock—4.44 million shares at $90.01 apiece—to kickstart the deal. Cambridge, MA-based Alnylam could get an...
Tags: Deals, Boston, Trends, Life Sciences, Clinical Trials, Alexion Pharmaceuticals, Regeneron, Cambridge MA, Regeneron Pharmaceuticals, Alnylam, Alnylam Pharmaceuticals, National blog main, New York blog main, New York top stories, Boston blog main, National top stories


Bio Roundup: Gottlieb’s Goodbye, AACR Recap, Migraine Drug Fight & More

Scott Gottlieb’s last day as FDA commissioner is today. His resignation announcement last month surprised some, given the earlier denials about leaving. But after two years of commuting between Connecticut, where his family remained, and the FDA’s Maryland headquarters, he decided to step down from the agency.What will Gottlieb’s legacy be? His efforts to curb teen vaping comes to mind. Or maybe it’s regulation. While Gottlieb remained mindful of the FDA’s oversight role, he also tried to strea...
Tags: Deals, Startups, Maryland, Breast Cancer, Trends, Investing, Lung Cancer, Connecticut, Cigna, Venture Capital, Fda, National, Novartis, Pfizer, Biotech, Insulin


Dyne Therapeutics Emerges With $50M to Take On Rare Muscle Disease

One problem with drugs for muscular disorders is that not enough medicine reaches the muscle, says Romesh Subramanian, CEO of Dyne Therapeutics. Subramanian’s startup has developed a way to deliver drugs to all muscle types, and it is emerging from stealth with $50 million in funding to advance its compounds toward human testing.Dyne was founded last year by Atlas Venture, which seeded and incubated the Cambridge, MA-based biotech. Atlas also invested in Dyne’s Series A funding announced Wednes...
Tags: Deals, Startups, Drugs, Boston, Trends, Investing, Atlas, Netherlands, Venture Capital, Cambridge, Fda, Biotech, Life Sciences, Clinical Trials, Biogen, Alexion Pharmaceuticals


EzCater Celebrates “Unicorn” Status After $150M Funding Round

Stefania Mallett was sitting at her kitchen table when she wrapped up the details behind her catering technology startup ezCater’s latest funding round, a $150 million investment.Mallett shared the details to her husband before the size of the occasion sank in.“I’m busy, already onto the next thing. He said, ‘Wait, that is a big number.’ I looked at him and it dawned on me: ‘That is a big number,'” Mallett recalled.That figure is the software company’s latest valuation by its investors: $1.25 b...
Tags: Deals, Boston, Restaurants, Singapore, CA, Trends, Tech, Vc, Paris, Vancouver, Tiger Global, Denver, Lightspeed Venture Partners, Iconiq Capital, Unicorn, Insight Venture Partners


SpringWorks, Armed with Ex-Pfizer Cancer Drugs, Reloads with $125M

SpringWorks Therapeutics, a startup spun out of Pfizer to develop drugs gathering dust on the New York pharma giant’s shelves, has closed its second nine-figure financing round in less than two years.The $125 million Series B funding gives the New York City startup the backing to bring two cancer drugs into what could be their final trials before regulatory approval, if all goes well. Perceptive Advisors led the round, but Springworks also has the backing of two pharma companies—Pfizer (NYSE: P...
Tags: Deals, Startups, New York, New York City, Trends, Vc, Fda, GlaxoSmithKline, Pfizer, Bain Capital, Life Sciences, GSK, OrbiMed Advisors, BeiGene, National blog main, New York blog main


Novartis Adds Inflammation Drugs to Pipeline with Deal for IFM Tre

Less than a year after launching and only days after advancing its lead program into clinical trials, drug developer IFM Tre is in line to be acquired by Novartis.According to an agreement announced Monday, Novartis (NYSE: NVS) will acquire all of the outstanding stock of privately held IFM. The Basel, Switzerland-based pharmaceutical giant will also pay IFM an upfront fee, plus milestone payments pegged to the progress of its experimental drugs. No other financial details of the agreement were...
Tags: Deals, Startups, Boston, Trends, Gout, Novartis, Biotech, Life Sciences, Clinical Trials, Basel Switzerland, Inflammation, National blog main, Boston blog main, Boston top stories, IFM, Novartis NYSE


Bio Roundup: Amyloid Angst, NASH News, Brammer Bagged & More

A week after , the ripple effects are still being felt—and not just by Biogen, which lost billions of dollars in market value in a flash.We’ll kick off this week’s roundup with the aducanumab reaction, which includes plenty of thoughts about the future of the so-called “amyloid hypothesis” and what’s next for another Biogen Alzheimer’s drug that has had mixed results.We’ll also check in on the gene therapy deal spree, the big week in national healthcare policy, and the preparations several com...
Tags: Deals, Obamacare, Trends, Alzheimer's Disease, Affordable Care Act, National, Pfizer, Medicaid, Xarelto, Federal Trade Commission, Life Sciences, Bayer, Clinical Trials, Celgene, Gilead Sciences, Eisai


Boston Tech Watch: Tinkergarten, ezCater, Glasswing Ventures & More

Tech to get your kids out into nature raises some big bucks from some Hollywood tech giants, while restaurant software and automated payments also make big moves. Read on for more Boston tech news:—Outdoor child-education network Tinkergarten raised $21 million from the consumer technology fund WndrCo run by former Disney (NYSE: DIS) chairman and DreamWorks co-founder Jeffrey Katzenberg and other media and tech veterans. The Northampton, MA-based company says it aims to help families connect wi...
Tags: Deals, Hollywood, Boston, Israel, Disney, Trends, Startup, Tech, Data, Mit, Vc, Northampton, Cambridge, Dreamworks, Fantasy Sports, Private Equity


Lyft Raises $2.2B in IPO, Pegging Valuation at Over $24B

Investors eager to bet on the mobility industry’s future handed ride-hailing company Lyft $2.2 billion in new capital Thursday as the company completed an IPO that set its market capitalization at $24.3 billion, The New York Times reported.Lyft sold 30.8 million shares at $72 apiece, according to Renaissance Capital—the top of a new range that Lyft originally set at $62 to $68. The company was valued at $15.1 billion at the time of its last fundraising in mid-2018.Lyft’s pricey showing rivals A...
Tags: Deals, Startups, Mobile, Lyft, Uber, Hardware, Marketplace, Pinterest, Entertainment, Internet, Entrepreneurship, Funding, US, San Francisco, Trends, Tech


Thermo Bags Brammer For $1.7B as Gene Therapy Deal Spree Continues

Thermo Fisher Scientific late Sunday evening agreed to buy Brammer Bio for $1.7 billion, yet another bet by a large biopharmaceutical organization on the future of gene therapy.Thermo (NYSE: TMO), a Waltham, MA, developer of lab equipment, made an all-cash offer for Cambridge, MA-based Brammer, a contract manufacturer of gene therapy delivery tools known as viral “vectors.”In a gene therapy procedure, these vectors—engineered viruses—are filled with genetic blueprints and infused into a patient...
Tags: Deals, Boston, Trends, Fda, Pfizer, Biotech, Life Sciences, Clinical Trials, TMO, Roche, Thermo Fisher Scientific, Biogen, Brammer, Cambridge MA, Gene Therapy, National blog main


Boston Tech Watch: Notarize, Optimus Ride, LogRocket & More

The self-driving cars are coming (to a gated development near you). Board additions at a novel tech startup. Another big funding round for an industrial 3D printing startup. The Endeavor v. QinetiQ robot competition’s final chapter. Read on for more.—Online notary startup Notarize is adding senior LogMeIn and State Street executives to its board. The Boston-based tech company says Larry D’Angelo, LogMeIn (NASDAQ: LOGM) chief sales officer, and Jack Klinck, former head of global strategy at Stat...
Tags: Boston, Boston blog main, Boston top stories, National blog main, 3D printing, Accomplice, Additive Manufacturing, Arlington, Army, Autonomous, Bae Systems, Battery Ventures, Ben Edelstein, Brex, Brooklyn Navy Yard, Burlington


CRISPR Diagnostic Race Heats Up as Sherlock Bio Launches With $35M

The high-stakes race to use CRISPR gene editing technology to create medicines has been underway for years now, and human trials are just starting. But the idea of using CRISPR as a tool to detect and diagnose a disease has been gaining traction, too, and the launch of a new startup today called Sherlock Biosciences marks the latest step.Sherlock has been formed around technologies licensed from the Broad Institute of MIT and Harvard University, dubbed “SHERLOCK” and “INSPECTR,” respectively, t...
Tags: Deals, Startups, Boston, Trends, Vc, Harvard University, Sherlock, Crispr, Illumina, Life Sciences, Jim Collins, Broad Institute of MIT, Jennifer Doudna, Gene Editing, Feng Zhang, David Walt


Flagship Reloads With $824M For Latest Growth Capital Fund

Flagship Pioneering, one of the Boston area’s top biotech company creators, has closed a new $824 million fund to help fuel the growth of its startups.The new fund—Special Opportunities Fund II—will complement the cash the firm uses to start its companies, much like the $285 million “Special Opportunities” fund the firm announced in 2016. In a statement, Flagship CEO Noubar Afeyan said the fund will provide “new capital to grow platform companies”—that is, startups based not on a single asset, ...
Tags: Deals, Startups, Boston, Trends, Vc, Life Sciences, Cambridge MA, Atlas Venture, National blog main, Boston blog main, Boston top stories, Denali Therapeutics, Noubar Afeyan, Moderna, Evelo Biosciences, Flagship Pioneering


Pfizer Bolsters Gene Therapy Position with $51M Vivet Deal

Pfizer this morning added to its methodical push into the gene therapy field, paying $51 million for a small stake in Vivet Therapeutics and the option to buy the Parisian biotech in the future.The deal is the latest in a recent string of investments by large biopharma companies in gene therapy, which offers the potential for a long-lasting, if not permanent effect through a one-time treatment. The field has gone through decades of ups and downs, but has now proven that it can develop approved ...
Tags: Deals, New York, Trends, Pfizer, Biotech, Life Sciences, Roche, Biogen, Gene Therapy, National blog main, New York blog main, New York top stories, Boston blog main, Spark Therapeutics, Rare diseases, Duchenne Muscular Dystrophy


Bio Roundup: Golumbeski’s Legacy, CRISPR Moratorium, Rebate Week & More

While all eyes in the biopharmaceutical world are currently trained on Bristol-Myers Squibb’s proposal to buy Celgene for $74 billion, it wasn’t that long ago that another company’s gaze was fixed on the Summit, NJ, drug maker.In the early 2000s, before the FDA approved Celgene’s flagship multiple myeloma drug lenalidomide (Revlimid), Novartis (NYSE: NVS considered buying the company. It passed, unwilling to risk billions on an unapproved drug. Those details came from biopharma dealmaker George...
Tags: Deals, Startups, China, Ipo, Cancer, Trends, Investing, Merck, Colorectal Cancer, Multiple Sclerosis, Harvard University, Health Insurance, Astrazeneca, Center For Medicare And Medicaid Services, Fda, National


X4 Completes Reverse Merger with Arsanis, Looks Ahead to Phase 3 Test

X4 Pharmaceuticals is the latest biotech to join the public markets, but it didn’t follow the IPO path to get there.Cambridge, MA-based X4 said Wednesday that it completed its “reverse merger” with Arsanis (NASDAQ: ASNS). Such business combinations enable a privately held company to go public by merging with a publicly traded business. Shares of the new X4 are set to begin trading on the Nasdaq exchange Thursday under the stock symbol “XFOR.”X4 is developing drugs that target the CXCR4 pathway,...
Tags: Deals, Drugs, Ipo, Boston, Trends, Cambridge, Biotech, Nasdaq, Life Sciences, Genzyme, National blog main, Boston blog main, Boston top stories, National Organization for Rare Disorders, X4 Pharmaceuticals, X4


Clinical Analytics Platform TriNetX Raises $40M to Speed Drug Trials

TriNetX, a Cambridge, MA developer of data analytics software for clinical research, has raised $40 million in a Series D funding round led by Merck’s corporate venture capital fund, the company said.The company’s analytics platform helps pharma companies detail the many aspects of a clinical trial—from choosing hospital locations with adequate populations of patients to managing what age ranges and other demographic variables to include in the studies—to cut down on delayed studies due to a re...
Tags: Deals, Boston, Massachusetts, Trends, Merck, Artificial Intelligence, Venture Capital, Cambridge, Machine Learning, Novartis, Pfizer, Delays, Protocol, Electronic Health Records, Amendments, Sanofi


The Life, Troubles, and Celgene Legacy of Deal Guru George Golumbeski

George Golumbeski is one of the most prolific dealmakers in the biopharmaceutical world. But the deal that changed his life is a pact he made with himself when he was ten years old.Playing with friends in front of his house in Hampton, VA, he watched his mother drag his dead-drunk father, a U.S. Air Force veteran who did a short stint in Vietnam, out of his car. Pretending to sleep in his bedroom, he’d often hear his parents screaming at each other.“I can’t end up like this,” he remembers think...
Tags: Deals, Ipo, Events, Trends, People, Depression, National, Novartis, Vietnam, Biotech, Illumina, New Enterprise Associates, Life Sciences, University Of Wisconsin, Genentech, UCB


Bright Cellars Uncorks $8.5M Round for Wine Subscription Service

A few years ago, the frothiest market in tech was arguably startups selling subscriptions to boxes of curated goods, such as clothing, beauty products, and food, which would arrive on customers’ doorsteps each month.The buzz around this area of e-commerce may have subsided a bit, but there are still a ton of box subscription startups plugging away. One of them, five-year-old Bright Cellars, apparently has amassed enough traction to score a fresh round of venture funding. The Milwaukee-based sta...
Tags: Deals, Startups, Milwaukee, Trends, Tech, Mit, Vc, Software, Aol, Wisconsin, Revolution Ventures, Steve Case, National blog main, Boston blog main, Xperience, San Francisco blog main


Beam Brings In $135M to Turn CRISPR Base Editing into Drugs

Beam Therapeutics made a splash last year when it launched with $87 million to develop medicines that use a more precise form of CRISPR editing. Beam’s promise of CRISPR-based therapeutics that swap out specific bases or “letters” in the genome—something the current generation of CRISPR-based drugs can’t do—has been so enticing to investors that they have put in $135 million in a Series B investment less than a year after the first funding round.CRISPR-Cas9 gene editing, which just last month e...
Tags: Deals, Startups, Boston, Trends, Venture Capital, Biotech, Crispr, Series B, Life Sciences, Broad Institute, Beam, Gene Editing, John Evans, National blog main, Boston blog main, National top stories


Cybersecurity on Tap: Agenda for Cyber Madness in Boston April 8

When it comes to cybersecurity, no one has all the answers. The best anyone can do is try to fend off cyber attacks with the latest technology and strategies, learn from their successes and failures, and maybe even share their experiences for the benefit of others.That last point is the goal of “Cyber Madness: Case Studies in Security,” a half-day forum Xconomy will host April 8 at EY’s offices in Boston’s Back Bay neighborhood. We’re assembling leading cybersecurity experts from New England an...
Tags: Deals, Startups, Mobile, Apps, Internet Of Things, Boston, Connected Devices, Trends, Tech, It, Cybersecurity, Vc, Software, Healthcare, M&a, Iot



Filters
show more filters
February - 2019
MoTuWeThFrSaSu
    123
45678910
11121314151617
18192021222324
25262728   
March - 2019
MoTuWeThFrSaSu
    123
45678910
11121314151617
18192021222324
25262728293031
April - 2019
MoTuWeThFrSaSu
1234567
891011121314
15161718192021
22232425262728
2930